Crucell 2009 Annual General Meeting of Shareholders 2008 Financial Statements Adopted; All Resolutions Approved

Leiden, The Netherlands (June 5, 2009) - Dutch biopharmaceutical company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announced that the Annual General Meeting of Shareholders (AGM) held today in Leiden adopted the 2008 financial statements. In addition, the AGM reappointed Mr. P. Satow and Mr. A. Hoevenaars as members of the Supervisory Board; Mr. Floris Waller was appointed as a new member of the Supervisory Board. The shareholders of Crucell were represented in person, by proxy voting, or by voting instruction, representing a total of 27% of the total issued share capital entitled to vote. The shareholders approved the appointment of Mr. Floris Waller as a member of the Supervisory Board. The appointment is for a term of four years, until 2013. Other members of the Supervisory Board, Mr. Philip Satow and Mr. Arnold Hoevenaars, were reappointed for a term of four years by Crucell's shareholders. Furthermore the AGM approved the 2008 financial statements and all other resolutions. At the meeting, presided by Jan Oosterveld, Chairman of the Supervisory Board, Ronald Brus, CEO of Crucell and Leon Kruimer, CFO discussed the company's 2008 results, reiterated the outlook for 2009 [1], and presented their views on the business and strategy of the company to shareholders. The slides of the presentation given at the AGM are available on the company's website Forward-looking statements This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on April 22, 2009, in the section entitled 'Risk Factors'. The Company prepares its financial statements under International Financial Reporting Standards (IFRS). About Crucell Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a global biopharmaceutical company focused on research development, production and marketing of vaccines, proteins and antibodies that prevent and/or treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminum-free hepatitis A vaccine on the market. The Company has a broad development pipeline, with several product candidates based on its unique PER.C6® production technology. The Company licenses its PER.C6® technology and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi-aventis, Novartis, Wyeth, GSK, CSL and Merck & Co. Crucell is headquartered in Leiden, the Netherlands, with subsidiaries in Switzerland, Spain, Italy, Sweden, Korea and the U.S. The Company employs over 1000 people. For more information, please visit For further information please contact: Crucell N.V. Oya Yavuz Vice President Corporate Communications & Investor Relations Tel. +31-(0)71-519 7064 [1] Total revenues and other operating income expected to grow 20% in constant currencies (Guidance currency = EUR/USD rate of 1.35); operating profit for 2009 expected to improve significantly compared to 2008; solid cash flow. This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.